FDA Drug · D-0203-2025

Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-079-93

Class II · Terminated

Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

Affected lots / codes — check yours against thisLot # 8181625, Exp 12/31/2025

Recalling firm: Viatris Inc, Canonsburg, PA
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 1,215/30 count bottles
Distribution: USA nationwide.
Recall initiated: December 23, 2024
Classified: January 16, 2025
Terminated: November 12, 2025
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0203-2025%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →